接受慢性丙型肝炎病毒感染治疗患者的C-C趋化因子受体2和C-C趋化因子受体5基因型

C-C chemokine receptor 2 and C-C chemokine receptor 5 genotypes in patients treated for chronic hepatitis C virus infection.

作者信息

Dorak M Tevfik, Folayan Gbolahan O, Niwas Santosh, van Leeuwen Dirk J, Yee Leland J, Tang Jianming, Kaslow Richard A

机构信息

Department of Epidemiology and International Health, School of Public Health, Comprehensive Cancer Center, University of Alabama at Birmingham, 35294-0022, USA.

出版信息

Immunol Res. 2002;26(1-3):167-75. doi: 10.1385/IR:26:1-3:167.

DOI:10.1385/IR:26:1-3:167

PMID:12403355

Abstract

We explored the influence of the major CCR5 promoter or coding region variants as haplotypes and genotypes in a cohort of 250 chronically infected HCV patients receiving combined interferon/ ribavirin therapy. No haplotype, including the D32-bearing haplotype (G2) reportedly associated in homozygotes with high HCV viral load (VL), showed a similar effect. Patients with genotype C/G2 showed slightly lower median VL (p = 0.05). Neither the G2 haplotype nor the C/G2 genotype influenced viral dynamics during the initial 12 wk of treatment (p = 0.53). The genotype E/E was more frequent among sustained responders (15.5%) than non-responders (7.8%), and VL declined further among E/E homozygotes during the initial 12 wk of treatment, particularly those with HCV genotype 1 (p = 0.016). Differential receptor expression due to E/E homozygosity in HCV infection remains to be confirmed.

摘要

我们在一组250例接受干扰素/利巴韦林联合治疗的慢性丙型肝炎病毒（HCV）感染患者中，探究了主要的CCR5启动子或编码区变体作为单倍型和基因型的影响。没有任何单倍型，包括据报道在纯合子中与高HCV病毒载量（VL）相关的携带D32的单倍型（G2），显示出类似的效果。基因型为C/G2的患者中位VL略低（p = 0.05）。在治疗的最初12周内，G2单倍型和C/G2基因型均未影响病毒动力学（p = 0.53）。持续应答者中E/E基因型（15.5%）比无应答者（7.8%）更常见，并且在治疗的最初12周内，E/E纯合子的VL进一步下降，尤其是HCV基因型1的患者（p = 0.016）。HCV感染中由于E/E纯合性导致的受体表达差异仍有待证实。